文献速递造血干细胞移植与细胞治疗

MAGIC算法概率(MAP)指导的甲泼尼龙抢先治疗急性移植物抗宿主病:一项随机对照试验

The MAGIC algorithm probability (MAP)-guided preemptive therapy of acute graft versus host disease with methylprednisolone: A randomized controlled trial.
PubMed 文献 · Am J Hematol · 2023-07-27

本研究在异基因造血干细胞移植后第7、14、21、28天检测ST2和Reg3α并计算MAP,将中高危患者随机分配接受或不接受甲泼尼龙抢先治疗。甲泼尼龙组100天2级及以上和3级及以上aGvHD累积发生率显著低于对照组,且与低危组相似;6个月NRM两组无显著差异。MAP指导的抢先治疗有前景,长期疗效和安全性有待研究。

要点

  • 甲泼尼龙组100天2级及以上aGvHD累积发生率为35.5%±8.6%,显著低于对照组的66.7%±7.9%(p=.01)。
  • 甲泼尼龙组100天3级及以上aGvHD累积发生率为12.9%±6.0%,显著低于对照组的42.9%±8.4%(p=.01)。
  • 甲泼尼龙组与对照组6个月NRM累积发生率分别为14.1%±6.6%和22.7%±7.1%,无显著差异(p=.29)。

核心结论

  • MAP指导的aGvHD抢先治疗有前景,长期疗效和安全性有待研究。

研究设计与样本

  • 在异基因造血干细胞移植后第7、14、21、28天检测ST2和Reg3α水平并计算MAP,据此将患者分为低危、中危或高危组。
  • 将中危或高危患者随机分配接受或不接受甲泼尼龙抢先治疗。

主要发现

  • 甲泼尼龙组100天2级及以上aGvHD累积发生率为35.5%±8.6%,显著低于对照组的66.7%±7.9%(p=.01),与低危组的31.7%±7.3%相似(p=.75)。
  • 甲泼尼龙组100天3级及以上aGvHD累积发生率为12.9%±6.0%,显著低于对照组的42.9%±8.4%(p=.01),与低危组的2.4%±2.4%相似(p=.08)。
  • 甲泼尼龙组、对照组和低危组6个月NRM累积发生率分别为14.1%±6.6%、22.7%±7.1%和2.4%±2.4%,甲泼尼龙组与对照组无显著差异(p=.29)。
  • 甲泼尼龙未增加感染(p=.34)。
  • 甲泼尼龙组、对照组和低危组100天CMV再激活累积发生率分别为67.7%±8.4%、65.6%±8.4%和46.3%±7.8%(p=.08),2级及以上出血性膀胱炎累积发生率分别为29.0%±8.2%、45.2%±8.9%和22.0%±6.5%(p=.11)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 长期疗效和安全性有待研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute graft versus host disease (aGvHD) is a severe complication that arises in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) and remains the primary cause of nonrelapse mortality (NRM). The MAGIC algorithm probability (MAP) has been proposed to identify patients at intermediate and high risk of developing aGvHD. The levels of suppression of tumorigenicity 2 (ST2) and regenerating islet-derived 3α (Reg3α) were assessed, and MAP was calculated on days 7, 14, 21, and 28 after allo-HSCT. Based on the MAP results, patients were classified into low-, intermediate-, or high-risk groups for the development of aGvHD. Random assignment was performed to allocate intermediate- or high-risk patients to receive preemptive therapy with methylprednisolone or not. The 100-day cumulative incidences of grade 2 or higher (35.5% ± 8.6%) and grade 3 or higher (12.9% ± 6.0%) aGvHD in the methylprednisolone group were significantly lower than those in the control group (66.7% ± 7.9%, p = .01; 42.9% ± 8.4%, p = .01), and similar to those observed in the low-risk group (31.7% ± 7.3%, p = .75; 2.4% ± 2.4%, p = .08). The 6-month cumulative incidences of NRM were 14.1% ± 6.6%, 22.7% ± 7.1%, and 2.4% ± 2.4% in the methylprednisolone, control, and low-risk groups, respectively, with no significant difference between the methylprednisolone and control groups (p = .29). Methylprednisolone did not increase infections (p = .34). The 100-day cumulative incidences of cytomegalovirus (CMV) reactivation were 67.7% ± 8.4%, 65.6% ± 8.4%, and 46.3% ± 7.8% (p = .08), and those of grade 2 or higher hemorrhagic cystitis were 29.0% ± 8.2%, 45.2% ± 8.9% and 22.0% ± 6.5% (p = .11) in the methylprednisolone, control, and low-risk groups, respectively. MAP-guided preemptive therapy for aGvHD is promising. The long-term efficacy and safety remain to be investigated.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Zeng Q, Zhang H, Kuang P, et al. The MAGIC algorithm probability (MAP)-guided preemptive therapy of acute graft versus host disease with methylprednisolone: A randomized controlled trial. Am J Hematol. 2023. PMID: 37497879. doi:10.1002/ajh.27020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。